Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income: 2014-2024

Historic Net Income for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to -$266.8 million.

  • Rocket Pharmaceuticals' Net Income rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Net Income of -$266.8 million as of FY2024, which was down 4.13% from -$256.2 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Income peaked at -$139.1 million during FY2020, and registered a low of -$266.8 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$256.2 million (2023), whereas its average is -$248.5 million.
  • Data for Rocket Pharmaceuticals' Net Income shows a maximum YoY crashed of 76.78% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Net Income stood at -$139.1 million in 2020, then declined by 20.15% to -$167.2 million in 2021, then tumbled by 33.00% to -$222.3 million in 2022, then decreased by 15.26% to -$256.2 million in 2023, then fell by 4.13% to -$266.8 million in 2024.